Merck and Schering-Plough said Tuesday they're moving ahead with plans to develop a combination cholesterol pill (Lipitor plus Zetia) that would be similar to Vytorin, despite the release of the ENHANCE data, raising questions about Vytorin's effectiveness.
"It is still in the works," Schering-Plough spokesman Lee Davies said. " Everything appears to be unchanged by the latest findings." Merck spokesman Skip Irvine confirmed that development plans were still on track.
Thanks Skip and Lee!
More
"It is still in the works," Schering-Plough spokesman Lee Davies said. " Everything appears to be unchanged by the latest findings." Merck spokesman Skip Irvine confirmed that development plans were still on track.
Thanks Skip and Lee!
More
No comments:
Post a Comment